Nimesulida Bluepharma (Nimesulide)

Nimesulide is indicated for conditions involving pain and inflammation.

• Mild to moderate pain: provides analgesic relief in adults with acute or chronic pain.
• Osteoarthritis: reduces joint inflammation and improves mobility in patients with osteoarthritis.
• Dysmenorrhea: alleviates menstrual pain associated with primary dysmenorrhea.

• Nimesulide selectively inhibits cyclooxygenase‑2 (COX‑2), decreasing the conversion of arachidonic acid to prostaglandins. This reduction in prostaglandin synthesis leads to lowered inflammation, pain, and fever responses at sites of tissue injury.

Adverse reactions may occur with Nimesulida Bluepharma and should be monitored.

Common Side Effects

• Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Skin rash or pruritus.
• Elevated liver enzymes.
• Mild increase in blood pressure.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury or failure.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Gastrointestinal ulceration or bleeding.
• Renal impairment or acute kidney injury.
• Anaphylactic reactions.
• Hematologic abnormalities such as agranulocytosis.

Before prescribing Nimesulida Bluepharma, clinicians should consider several safety measures.

• Assess liver function: evaluate baseline hepatic enzymes before initiating therapy.
• Avoid in patients with known hypersensitivity to nimesulide or other NSAIDs.
• Use caution in patients with cardiovascular disease: monitor for increased thrombotic risk.
• Limit duration in elderly: reduce risk of gastrointestinal complications.
• Avoid concomitant use with other COX‑2 inhibitors or high‑dose aspirin.
• Store at room temperature: keep in the original pack, protect from moisture and light.

Nimesulida Bluepharma can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Concurrent use with other NSAIDs or COX‑2 inhibitors: increased risk of gastrointestinal bleeding.
• Strong CYP2C9 inhibitors (e.g., fluconazole): may raise nimesulide plasma levels.
• Anticoagulants (e.g., warfarin): heightened bleeding risk.
• Lithium: NSAIDs may increase lithium serum concentrations.
• Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may reduce renal clearance of nimesulide.
• ACE inhibitors or ARBs: potential for reduced renal function.
• Corticosteroids: additive risk of gastrointestinal ulceration.
• Selective serotonin reuptake inhibitors: increased bleeding tendency.
• Alcohol: may exacerbate liver toxicity.